Photronics is a profitable photomask supplier whose shares reset hard after the May 2026 IC design-release slowdown. The balance sheet is unusually liquid, with net cash of about $633.8M, but the base case no longer supports a simple high-growth semiconductor multiple because Q3 guidance, litigation risk and high-end IC visibility all deteriorated.
The core multiple starts from peer EV/EBITDA, then applies a numeric 8% discount for guidance risk and design-release visibility. The second-method check is analyst consensus of $42.33, last updated 2026-07-02, which is effectively in line with the computed $42.75 base case. Sensitivity: each 1.0x EBITDA multiple point changes fair value by about $3.99/sh. Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Core photomask EV | $235M FY26E EBITDA x 7.4x target EV/EBITDA / 58.96M shares | +29.50 |
| Net cash | ($637.67M cash and investments - $3.86M debt) / 58.96M shares | +10.75 |
| High-end IC recovery option | 20% probability x $450M value if stalled design releases normalize / 58.96M shares | +1.53 |
| FPD / AMOLED option | 25% probability x $300M value from advanced mask-writer and AMOLED momentum / 58.96M shares | +1.27 |
| Capital return option | 35% probability x $150M buyback / capital return capacity / 58.96M shares | +0.89 |
| Litigation and execution reserve | $70M reserve for securities class action, capex delay and guidance-reset risk / 58.96M shares | -1.19 |
| FV base case | Exact sum: 29.50 + 10.75 + 1.53 + 1.27 + 0.89 - 1.19 | 42.75 |
The capital-structure thesis is the opposite of distress: $633.8M net cash, current ratio of 5.05 and debt/EBITDA of 0.01x. The analytical issue is whether JV cash, heavy capex and litigation reserve reduce the amount that common shareholders can treat as deployable.
| Item | FY2023 | FY2024 | FY2025 | TTM May 2026 | Guidance / FY26E |
|---|---|---|---|---|---|
| Revenue | $892.1M | $867.0M | $849.3M | $861.2M | $859.4M consensus |
| Operating income | $253.1M | $221.5M | $208.2M | $197.3M | $180.4M consensus |
| Net income | $125.5M | $130.7M | $136.4M | $159.1M | $122.8M consensus |
| Free cash flow | $170.9M | $130.5M | $59.7M | $96.3M | Capex still elevated |
| Gross margin | 37.7% | 36.4% | 35.3% | 33.8% | 32.3% FY26E |
| Metric | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue ($M) | 210.9 | 211.0 | 215.9 | 225.1 | 209.9 |
| Gross margin % | 36.9% | 35.4% | 34.8% | 36.1% | 31.3% |
| Net income ($M) | 8.9 | 29.1 | 61.8 | 42.9 | 31.4 |
| Cash & investments EOP ($M) | 512.2 | 548.0 | 588.2 | 636.9 | 637.7 |
Business model - photomasks for IC and FPD manufacturing
Integrated Circuit photomasks ~$590M TTM est. (about 68% rev) red reset Core profit pool. Q2 FY26 IC revenue was $147.5M, down 11% sequentially, due to delayed design releases and customer schedule friction. Flat Panel Display photomasks ~$250M TTM est. (about 29% rev) green ramping FPD revenue was $62.4M in Q2 FY26, up 13% year over year and 4% sequentially. AMOLED activity and advanced mask-writer capacity are the main upside path. Regional high-end capacity U.S., Korea, Taiwan, China footprint yellow to prove U.S. and Korea expansion can increase strategic relevance, but the company must prove that capex converts into high-end utilization rather than excess fixed cost.
Legal, regulatory and risk analysis
SWOT analysis
- +Net cash equal to about $10.75 per share.
- +Profitable through the cycle with 22.9% TTM operating margin.
- +Global footprint with 11 manufacturing facilities.
- +FPD segment still growing despite the IC reset.
- −Demand visibility is short and backlog is not a strong long-cycle anchor.
- −FY26 EPS expected to decline despite buybacks.
- −JV cash reduces the practical value of headline liquidity.
- −Insider selling weakens governance optics.
- →Q3 FY26 can show whether design-release delays are temporary.
- →AMOLED and high-end masks can recover investor confidence.
- →Further buybacks at low EV/EBITDA can be accretive.
- →Strategic U.S. trusted-mask positioning may gain value.
- !Another guidance miss would compress the multiple toward tangible book.
- !Class-action developments can create settlement and disclosure risk.
- !Memory supply and OEM cost pressure may defer design launches.
- !Capex-heavy expansion can dilute FCF if utilization disappoints.
Summary by assessment area
- Net cash and liquidity are the strongest parts of the thesis.
- Debt does not drive the downside case.
- The business must prove that IC delays are temporary.
- Q3 guidance is the key near-term operating test.
- Class action and insider selling require a valuation reserve.
- No operational thesis should ignore disclosure credibility.
Sources: Price/market data - StockAnalysis/S&P Global Market Intelligence history and quote showing PLAB $32.99 at close 2026-08-11; TradingView quote page as secondary price check showing PLAB current price $32.99. Market data - last verified close 2026-08-11: PLAB $32.99, market cap ~$1.95B, 52W range $18.61-$56.00, 58.96M shares outstanding. Short interest: 7.38% float. IR/filings - Photronics Q2 FY26 release, SEC 8-K exhibit and 10-Q for the quarter ended 2026-05-03. Financial history - StockAnalysis/Fiscal.ai financials and balance sheet. Market cap/shares/52W - StockAnalysis statistics and history, TradingView quote, MarketBeat profile. Short interest - StockAnalysis/S&P statistics. Analyst target - StockAnalysis/S&P and TipRanks forecast, last updated 2026-07-02; latest targets: Freedom $41 on 2026-07-02, Craig-Hallum $42 on 2026-05-29, Lake Street $55 on 2026-05-28. Governance/insider/class action - MarketBeat insider-trades page, PRNewswire class-action notices, Kessler Topaz case page and SEC Form 4 index. Peer comparables - AMKR, COHU, KLIC and UCTT from StockAnalysis/Yahoo/market-data snapshots. This document is for informational purposes only and does not constitute financial or investment advice.